ClinicalTrials.gg
Active, not recruitingNCT05048797Updated Oct 21, 2026

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

A Phase 3 interventional study of Trastuzumab Deruxtecan and Cisplatin in Locally Advanced or Metastatic Non-Small Cell Lung Cancer, sponsored by AstraZeneca. Active, not recruiting at 130 sites in 20 countries. Open to participants aged 18 Years to 123 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
454
Allocation
Randomized
Ages
18 Years to 123 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing trastuzumab deruxtecan in Carcinoma, Non-Small-Cell Lung — 5 open to participants now, 9 under way, 2 of them phase 3. trastuzumab deruxtecan · Carcinoma, Non-Small-Cell Lung.

Enrollment
3rd of 12
454 · median 167
Started
2021
with 2 others
Phase 3
2 of 12
1 open now
Registered
6th of 12
by date
Lead sponsor
4 of 12
AstraZeneca

Among the 12 studies testing trastuzumab deruxtecan in Carcinoma, Non-Small-Cell Lung, this one is the 3rd largest by enrollment, is one of 3 that started in 2021, is one of 2 in phase 3, and was the 6th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

5 of the 12 studies testing trastuzumab deruxtecan in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About trastuzumab deruxtecan

trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 123 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing trastuzumab deruxtecan in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

DESTINY-Lung04 will investigate the efficacy and safety of Trastuzumab Deruxtecan (T-DXd) versus Standard of Care (SoC) as first-line treatment of Non-Small Cell Lung Cancer (NSCLC) with HER2 Exon 19 or 20 mutations

Read the detailed description

Eligible participants will be those diagnosed with unresectable, locally advanced or metastatic histologically documented non-squamous NSCLC with HER2 exons 19 or 20 mutations and who are treatment-naïve for palliative intent systemic therapy for locally advanced or metastatic disease.

The study aims to evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan as first-line treatment of Non-Small Cell Lung Cancer (NSCLC) as compared with Standard of Care treatment (Investigator's choice of cisplatin or carboplatin + pembrolizumab + pemetrexed). This study aims to see if trastuzumab deruxtecan allows patients to live longer without the cancer getting worse or simply to live longer, compared to patients receiving standard of care treatment. This study is also looking to see how the treatment and the cancer affects patients' quality of life.

03

Conditions studied

  • Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Keywords

  • DS-8201a
  • HER2 exon 19 or 20 mutations
  • ERBB2 gene (coding for the HER2 protein)
  • T-DXd
  • Trastuzumab Deruxtecan
  • Locally advanced and unresectable non-squamous NSCLC
  • Metastatic non-squamous NSCLC
  • Non-small cell lung cancer
04

Who can participate

Ages eligible
18 Years to 123 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants at least 18 years of age
  • Locally advanced and unresectable NSCLC, not amenable to curative therapy, or disease
  • documented non-squamous NSCLC with mutation in exons 19 or 20 by tissue NGS or ctDNA
  • Treatment-naïve for palliative intent systemic therapy for locally advanced or metastatic disease
  • (LVEF) ≥ 50%
  • assessed by Investigator based on 1.1
  • Protocol-defined adequate organ function including cardiac, renal, hepatic function
  • 0-1
  • Having tumour tissue available for central testing

Exclusion criteria

Exclusion Criteria:

  • Tumors with targetable alterations to EGFR (or other targetable mutations including but not limited to ALK, if routinely tested as a targetable alteration with approved available therapy)
  • Any untreated , including asymptomatic or clinically inactive brain metastases
  • Active or inflammatory disorders
  • Medical history of myocardial infarction within 6 months prior to randomization
  • History of non-infectious pneumonitis/ILD, current or suspected ILD
  • Lung-specific intercurrent clinical significant severe illness
  • to platinum-based doublet chemotherapy or pembrolizumab
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
454 participants (actual)

Study arms

  • Experimental
    Arm 1

    Trastuzumab Deruxtecan (T-DXd)

    Drug: Trastuzumab Deruxtecan

  • Active comparator
    Arm 2

    Standard of Care Treatment (platinum, pemetrexed and pembrolizumab)

    Drug: Cisplatin · Drug: Carboplatin · Drug: Pembrolizumab · Drug: Pemetrexed

Interventions

  • Trastuzumab Deruxtecan administered by intravenous infusion

    Also known as: DS-8201a; T-DXd

  • Investigator's choice of platinum chemotherapy (cisplatin) administered by intravenous infusion

  • Investigator's choice of platinum chemotherapy (carboplatin) administered by intravenous infusion

  • Pembrolizumab administered by intravenous infusion

  • Pemetrexed administered by intravenous infusion

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)

    Defined as time from randomization until progression per RECIST 1.1 as assessed by Blinded Independent Central Review (BICR), or death due to any cause.

    Time frame: Until progression or death, assessed up to approximately 12 months

Secondary outcomes

  1. Overall Survival (OS)

    Defined as time from randomization until the date of death due to any cause.

    Time frame: Until death, assessed up to approximately 28 months.

  2. Progression Free Survival (PFS) by investigator assessment

    Defined as time from randomization until progression per RECIST 1.1 as assessed by the investigator, or death due to any cause.

    Time frame: Until progression, assessed up to approximately 12 months

  3. Objective Response Rate (ORR)

    Defined as the proportion of participants who have a complete response (CR) or partial response (PR) as assessed by Blinded Independent Central Review (BICR) and investigator according to RECIST 1.1

    Time frame: Until progression, assessed up to approximately 12 months

  4. Duration of Response (DoR)

    Defined as the time from the date of first documented response until date of documented progression as assessed by Blinded Independent Central Review (BICR) and investigator assessment according to RECIST 1.1.

    Time frame: Until progression, assessed up to approximately 12 months

  5. Time to second progression or death (PFS2)

    Defined as the time from randomization until second progression on next-line of treatment as assessed by investigator at the local site using assessments conducted per local standard clinical practice, or death due to any cause.

    Time frame: Assessed up to approximately 20 months

  6. Landmark analysis of PFS (PFS12)

    Defined as proportion of participants alive and progression-free at 12 months, as assessed by Blinded Independent Central Review (BICR) and investigator.

    Time frame: Assessed up to approximately 12 months

  7. Landmark analysis of OS (OS24)

    Defined as proportion of participants alive at 24 months

    Time frame: Assessed up to approximately 24 months

  8. Central Nervous System (CNS) - Progression Free Survival (PFS)

    Defined as time from randomization until Central Nervous System (CNS) progression per RECIST 1.1 as assessed by Blinded Independent Central Review (BICR) or death due to any cause in the absence of CNS progression.

    Time frame: Until CNS progression or death, assessed up to approximately 12 months

  9. Safety and tolerability of T-DXd versus Standard of Care treatment

    Assessed by the occurrence of AEs, SAEs, and changes from baseline in laboratory parameters, vital signs, ECG, and ECHO/MUGA scan results.

    Time frame: Until progression or death, assessed up to approximately 28 months

  10. Pharmacokinetics (PK) of T-DXd, total anti-HER2 antibody and DXd in serum

    Serum concentration of T-DXd, total anti-HER2 antibody and DXd.

    Time frame: Up to cycle 4, approximately 12 weeks

  11. Immunogenicity of T-DXd

    Presence of anti-drug antibodies (ADAs) for T-DXd.

    Time frame: Until progression, assessed up to approximately 13 months

  12. Patient-reported pulmonary symptoms associated with Non-Small Cell Lung Cancer

    Time to sustained deterioration in pulmonary symptoms (cough, dyspnea, chest pain) while on treatment using the Non-Small Cell Lung Cancer-Symptom Assessment Questionnaire (NSCLC-SAQ).

    Time frame: Until progression, assessed up to approximately 13 months

  13. Patient-reported tolerability of T-DXd described using symptomatic AEs

    Symptomatic AEs: Descriptive summary of the proportion of participants reporting symptomatic AEs while on treatment, as assessed by the Patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) and items from the European Organisation for Research and Treatment of Cancer (EORTC) Item Library.

    Time frame: Until progression, assessed up to approximately 13 months

  14. Patient-reported tolerability of T-DXd described using overall side-effect bother

    Overall side-effect bother: Descriptive summary of the proportion of participants reporting overall side-effect bother on the Patient's Global Impression of Treatment Tolerability (PGI-TT) while on treatment.

    Time frame: Until progression, assessed up to approximately 13 months

  15. Patient-reported tolerability of T-DXd described using physical function

    Physical Function: The proportion of participants with maintained or improved physical function while on treatment, based on the European Organisation for Research and Treatment of Cancer 30-item core quality of life questionnaire (EORTC-QLQ-C30) physical functioning scale.

    Time frame: Until progression, assessed up to approximately 13 months

07

Study locations

130 sites
  • Research Site
    Anchorage, Alaska 99508, United States
  • Research Site
    Los Alamitos, California 90720, United States
  • Research Site
    Los Angeles, California 90048, United States
  • Research Site
    Orange, California 92868, United States
  • Research Site
    San Francisco, California 94143, United States
  • Research Site
    Santa Monica, California 90404, United States
  • Research Site
    Silver Spring, Maryland 20910, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    Ann Arbor, Michigan 48109, United States
  • Research Site
    Basking Ridge, New Jersey 07920, United States
  • Research Site
    Middletown, New Jersey 07748, United States
  • Research Site
    Montvale, New Jersey 07645, United States
  • Research Site
    New Brunswick, New Jersey 08901, United States
  • Research Site
    Commack, New York 11725, United States
  • Research Site
    Harrison, New York 10604, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Uniondale, New York 11553, United States
  • Research Site
    Pittsburgh, Pennsylvania 15232, United States
  • Research Site
    Dallas, Texas 75246, United States
  • Research Site
    Linz, 4020, Austria
  • Research Site
    Vienna, 1210, Austria
  • Research Site
    Ghent, 9000, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Barretos, 14784-400, Brazil
  • Research Site
    Blumenau, 89010-340, Brazil
  • Research Site
    Brasília, 70200-730, Brazil
  • Research Site
    Natal, 59075-740, Brazil
  • Research Site
    Salvador, 40170-110, Brazil
  • Research Site
    São Paulo, 01321-001, Brazil
  • Research Site
    São Paulo, 01327-001, Brazil
  • Research Site
    Uberlândia, 38408-150, Brazil
  • Research Site
    Vancouver, British Columbia V5Z 4E6, Canada
  • Research Site
    Brampton, Ontario L6R 3J7, Canada
  • Research Site
    Toronto, Ontario M5G 1Z5, Canada
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
  • Research Site
    Beijing, 100142, China
  • Research Site
    Beijing, 100730, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Changsha, 410008, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chengdu, 611135, China
  • Research Site
    Fuzhou, 350014, China
  • Research Site
    Guangzhou, 510080, China
  • Research Site
    Hangzhou, 310020, China
  • Research Site
    Jinan, 250117, China
  • Research Site
    Kunming, 650101, China
  • Research Site
    Kunming, 650118, China
  • Research Site
    Linhai, 317000, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Nanjing, 210029, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shenyang, 110016, China
  • Research Site
    Shenzhen, 518020, China
  • Research Site
    Wenzhou, CN-325000, China
  • Research Site
    Wuhan, 430022, China
  • Research Site
    Xi'an, 710061, China
  • Research Site
    Xiamen, 361003, China
  • Research Site
    Yangzhou, 225001, China
  • Research Site
    Vejle, 7100, Denmark
  • Research Site
    Bordeaux, 33000, France
  • Research Site
    Dijon, 21079, France
  • Research Site
    Le Mans, 72037, France
  • Research Site
    Lyon, 69373, France
  • Research Site
    Marseille, 13915, France
  • Research Site
    Nantes, 44093, France
  • Research Site
    Toulouse, 31059, France
  • Research Site
    Villejuif, 94805, France
  • Research Site
    Cologne, 50937, Germany
  • Research Site
    Dresden, 01307, Germany
  • Research Site
    Mainz, 55131, Germany
  • Research Site
    München, 81377, Germany
  • Research Site
    Oldenburg, 26121, Germany
  • Research Site
    Hong Kong, 999077, Hong Kong
  • Research Site
    Hong Kong, Hong Kong
  • Research Site
    Jordan, 999077, Hong Kong
  • Research Site
    Bangalore, 560027, India
  • Research Site
    Delhi, 110085, India
  • Research Site
    Hyderabad, 500032, India
  • Research Site
    Mumbai, 400012, India
  • Research Site
    Nashik, 422002, India
  • Research Site
    Milan, 20141, Italy
  • Research Site
    Monza, 20090, Italy
  • Research Site
    Orbassano, 10043, Italy
  • Research Site
    Parma, 43126, Italy
  • Research Site
    Roma, 00168, Italy
  • Research Site
    Verona, 37134, Italy
  • Research Site
    Chūōku, 104-0045, Japan
  • Research Site
    Fukuoka, 812-8582, Japan
  • Research Site
    Kashiwa, 277-8577, Japan
  • Research Site
    Matsuyama, 791-0280, Japan
  • Research Site
    Niigata, 951-8566, Japan
  • Research Site
    Okayama, 700-8558, Japan
  • Research Site
    Osaka, 541-8567, Japan
  • Research Site
    Sakai, 590-0197, Japan
  • Research Site
    Sapporo, 060-8638, Japan
  • Research Site
    Sendai, 981-0914, Japan
  • Research Site
    Sunto-gun, 411-8777, Japan
  • Research Site
    Yokohama, 241-8515, Japan
  • Research Site
    Yonago-shi, 683-8504, Japan
  • Research Site
    Mexico City, '14080, Mexico

Showing the first 100 of 130 sites across 20 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Jun 2026, 55 months.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 55 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2021
First posted
Sep 17, 2021
StartActual
Oct 28, 2021
Primary completionActual
Jun 9, 2026
CompletionEst.
Jul 30, 2027
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers, verification date and site details
1 update, last Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Minor edits only
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05048797
Lead sponsor
AstraZeneca
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
Sep 17, 2021
Start date
Oct 28, 2021
Primary completion
Jun 9, 2026
Completion
Jul 30, 2027 (estimated)
Last update
Oct 21, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab deruxtecan

Start the discussion